Target Readiness Index™ (TRI): CRISPR Target Prioritization Autoimmune Disease & IACCs
- Apr 14
- 14 min read
Updated: 4 days ago
A State-Dependent Gene Target Prioritization Framework for Immune-Volatile Disease
By Cynthia Adinig
Key Findings and Summary
Gene-editing strategies have advanced rapidly across oncology and monogenic disease, yet their translation into complex chronic illness remains limited. This gap is not driven by a lack of biological targets, but by a failure to account for instability within the host system. Conditions such as ME/CFS, Long COVID, chronic Lyme disease, lupus, type 1 diabetes, complex regional pain syndrome (CRPS), Hashimoto’s thyroiditis, and Sjögren’s syndrome differ in origin, but share a common constraint: intervention must occur within unstable, timing-sensitive biological systems.
Emerging CRISPR applications in cancer and autoimmune disease demonstrate that successful outcomes depend not only on target selection, but also on system context, inflammatory burden, and intervention timing (Hsu et al., 2014; Frangoul et al., 2021; Mullard, 2023). These findings highlight a critical limitation in current prioritization models, which assume stable physiology and predictable response patterns that do not reflect real-world patient populations.
The Target Readiness Index™ (TRI) introduces a state-dependent framework for CRISPR target prioritization across infection-associated, autoimmune, and neuroimmune disease environments. This model evaluates gene targets based on edit precedent, safety complexity, phenotype specificity, timing sensitivity, and system interaction load, shifting the focus from static molecular relevance to dynamic intervention readiness. This approach aligns with CYNAERA’s CRISPR Remission™ framework, which models gene-editing strategies within fluctuating immune states, and extends across autoimmune disease applications including lupus, type 1 diabetes, and CRPS. By integrating timing, system interaction, and real-world instability, TRI establishes a scalable method for safer and more effective gene-editing deployment in immune-volatile disease.
Background and Problem Framing
Gene editing technologies have been optimized within relatively stable disease models, including hematologic disorders and oncology, where intervention conditions can be controlled and outcomes more easily attributed to specific molecular changes (Hsu et al., 2014; Doudna, 2020). These environments have shaped current target prioritization strategies, which emphasize pathway relevance and gene function without accounting for systemic variability. In contrast, immune volatile conditions operate within continuously shifting physiological states.
Patients experience cycles of immune activation and suppression, metabolic dysfunction, autonomic disruption, and neurological involvement that do not follow linear progression patterns. These dynamics introduce variability that cannot be captured by static prioritization models and significantly influence intervention safety and effectiveness. This instability is not limited to infection-associated conditions. Autoimmune diseases such as lupus, type 1 diabetes,
Hashimoto’s thyroiditis, and Sjögren’s syndrome demonstrate similar patterns of fluctuating immune activity, tissue-specific targeting, and systemic spillover. These shared characteristics complicate gene-editing strategies by narrowing the window in which intervention can occur safely.
In ME/CFS and related conditions, this challenge is particularly visible. Post-exertional malaise, environmental sensitivity, and autonomic instability create a highly constrained physiological environment where even biologically appropriate targets may produce adverse outcomes if applied during periods of instability (Institute of Medicine, 2015; Komaroff and Lipkin, 2021). Similar constraints are increasingly recognized in autoimmune disease, where flare cycles and inflammatory variability shape treatment response.
Traditional gene-editing models fail to incorporate these constraints, leading to a disconnect between target identification and real-world application. A gene may be highly relevant within a pathway but still unsuitable for intervention if system conditions are not stable enough to support safe modification. CYNAERA’s SymCas™ model has consistently demonstrated that timing and system state are critical determinants of outcome in immune-volatile disease. TRI extends this principle into gene-editing prioritization, reframing target selection as a function of readiness rather than relevance alone.
CRISPR Target Selection in Complex Disease
Current CRISPR target prioritization strategies have been developed within disease models that assume relative physiological stability. These approaches emphasize molecular function, gene expression patterns, and pathway centrality, often without incorporating the dynamic conditions present in chronic multi-system disease (Hsu et al., 2014; Doudna, 2020). This limitation becomes significant when applying CRISPR-based interventions to conditions such as ME/CFS, Long COVID, chronic Lyme disease, and autoimmune illnesses. In these environments, immune signaling pathways shift between activation and suppression states, metabolic systems fluctuate under stress, and environmental triggers can rapidly alter disease severity. These factors directly impact both the safety and effectiveness of gene-editing interventions.
Recent advances in CRISPR-based therapies for autoimmune disease highlight this challenge. Gene modified immune cell therapies and targeted pathway interventions demonstrate that autoimmune targets are accessible to gene editing, but also reveal a critical dependency on timing, system stability, and inflammatory context (Mullard, 2023). This dependency mirrors patterns observed in infection-associated chronic conditions, reinforcing the need for a unified prioritization framework.
TRI addresses this gap by introducing timing-aware gene target evaluation across both infection-associated and autoimmune disease environments. Rather than selecting targets based solely on biological relevance, the framework evaluates whether a target can be safely and effectively modified within a fluctuating system. This approach aligns with CYNAERA’s CRISPR Remission™ model, which treats gene editing as a state-dependent process that integrates phenotype, timing, environmental load, and system interaction. Within this framework, autoimmune diseases including lupus, type 1 diabetes, Hashimoto’s thyroiditis, and Sjögren’s syndrome are not separate categories, but part of a broader class of immune-volatile conditions requiring readiness-based intervention logic. By reframing CRISPR target prioritization in this way, TRI defines a new approach to gene editing in complex disease, one that prioritizes system stability, timing, and cross-condition applicability alongside molecular targeting.
Framework Architecture and Core Domains
The Target Readiness Index™ evaluates gene targets through a multi-domain framework designed for unstable biological systems. This model reflects both established gene-editing principles and observed patterns across immune-volatile conditions, including infection-associated and autoimmune disease.
Edit Precedent
This domain assesses whether a gene or pathway has been successfully edited, modulated, or therapeutically targeted in other conditions. Evidence from CRISPR-based therapies, CAR-T applications, and gene-modulation strategies provides a baseline for feasibility and translational potential (Frangoul et al., 2021; Mullard, 2023). Targets with strong precedent carry lower uncertainty, particularly when supported by clinical or preclinical validation.
Safety Complexity
Safety complexity evaluates the likelihood that modifying a target will destabilize adjacent systems. Many relevant pathways in ME/CFS, autoimmune disease, and neuroimmune conditions sit within tightly coupled networks, including cytokine signaling, autonomic regulation, and mast cell activation. Disruption within these networks can propagate across systems, amplifying instability rather than resolving it.
Phenotype Specificity
This domain measures how directly a target maps to a defined symptom cluster or functional impairment. Higher specificity improves predictability and enables alignment with subgroup-based intervention strategies. This reflects broader movement toward precision medicine, where treatment is guided by phenotype rather than diagnosis alone (Ashley, 2016).
Timing Sensitivity
Timing sensitivity evaluates the degree to which intervention success depends on physiological stability. In immune-volatile disease, even well-selected targets may fail if introduced during active flare states or periods of heightened immune activation. This constraint is observed across both infection-associated conditions and autoimmune illnesses such as lupus, Hashimoto’s thyroiditis, and Sjögren’s syndrome.
System Interaction Load
System interaction load quantifies the number and intensity of downstream systems affected by modifying a target. High interaction load increases the probability of unintended cascade effects, particularly in multi-system conditions where immune, neurological, metabolic, and endocrine pathways are already interconnected. These domains operate as an integrated system rather than independent variables. Their interaction defines overall readiness, allowing TRI to move beyond binary target selection toward a nuanced prioritization model that reflects real-world biological complexity.
Readiness Classification and Operational Use
The TRI framework organizes gene targets into three operational tiers based on their composite readiness profile. This structure enables dynamic prioritization while maintaining consistency across disease categories.
Chart: TRI Readiness Classification
Tier | Classification | Operational Meaning | Example Targets |
Tier 1 | Deployment-Ready | High feasibility with timing control required | PDCD1, KIT, RAAS pathway |
Tier 2 | Conditional Targets | State-dependent use requiring stabilization | PPARGC1A, NLRP3, VEGFA, CX3CR1 |
Tier 3 | Exploratory Targets | Model-driven use for simulation and refinement | BDNF, GRIN2A, IRF7, AHR |
Tier 1 targets demonstrate strong precedent and clear phenotype mapping, but require precise timing to avoid destabilization. Their use is best suited to controlled environments where system stability can be verified prior to intervention. Evidence from immune checkpoint therapies and targeted interventions supports the feasibility of these approaches when timing is appropriately managed (Topalian et al., 2012; Robert et al., 2015).
Tier 2 targets represent biologically significant pathways that require stricter readiness thresholds. These targets often sit within complex signaling networks and may produce variable outcomes depending on immune state, inflammatory load, and environmental conditions. Their use is best guided by simulation models and subgroup stratification.
Tier 3 targets are primarily valuable for modeling, pathway exploration, and subgroup refinement. These targets contribute to understanding disease mechanisms across ME/CFS, autoimmune disease, and neuroimmune conditions, but are not currently suitable as primary intervention anchors.
The following operational principles guide TRI application:
Targets are dynamic and may shift between tiers based on patient state and environmental conditions.
Intervention decisions depend on system stabilization rather than target availability alone.
Phenotype alignment is required before any intervention is considered.
Timing thresholds must be met before transitioning from theoretical to actionable use.
Simulation frameworks are used to evaluate Tier 2 and Tier 3 targets prior to deployment.
This classification system transforms target prioritization into a state-dependent process that adapts to real-time biological conditions, rather than relying on static assumptions.
Validation Across Autoimmune and Immune-Volatile Disease
TRI was developed within CYNAERA’s broader CRISPR Remission™ framework for immune-volatile disease, where timing, system interaction, and environmental context determine intervention safety. Although the readiness problem is especially visible in ME/CFS, Long COVID, and chronic
Lyme disease, it is equally relevant across autoimmune and neuroimmune conditions. In systemic lupus erythematosus, immune dysregulation fluctuates across organ systems, with periods of relative stability interrupted by acute inflammatory activation. In type 1 diabetes, immune targeting of pancreatic beta cells reflects a persistent but dynamically modulated autoimmune process.
In complex regional pain syndrome (CRPS), neuroimmune signaling and inflammatory cascades create a similarly unstable intervention environment. Related autoimmune conditions such as Hashimoto’s thyroiditis and Sjögren’s syndrome exhibit comparable patterns of instability, including variable immune activation, endocrine disruption, and systemic symptom fluctuation. These shared features reinforce the need for timing-aware intervention models that extend beyond condition-specific frameworks.
Gene editing approaches in these conditions face the same core constraint observed in infection-associated chronic illness: biologically relevant targets may still be unsafe or ineffective if applied during periods of instability. Emerging CRISPR applications in autoimmune disease, including gene-modified immune therapies and pathway-targeted interventions, highlight the importance of timing, system context, and cross-system interaction in determining outcomes (Mullard, 2023; Georgiadis et al., 2022).
TRI provides a consistent framework for addressing this challenge across disease categories. By evaluating targets based on timing sensitivity, system interaction load, and phenotype alignment, the model enables cross-condition prioritization without requiring disease-specific redesign. This establishes TRI not as a condition specific tool, but as a generalized readiness framework for immune-volatile disease, spanning infection associated conditions, autoimmune illness, and neuroimmune disorders within a unified system.
Application in Immune-Volatile Patients
TRI is designed to operate within real-world clinical complexity, where patient presentation rarely aligns with simplified disease models. Its application reflects the layered nature of immune-volatile conditions, where multiple systems interact simultaneously and intervention outcomes depend on timing, environmental context, and system stability.
A patient presenting with severe post-exertional malaise, environmental sensitivity, and mild autonomic instability represents a common phenotype across ME/CFS and related conditions. Traditional models might prioritize immune modulation broadly, focusing on inflammatory pathways without accounting for timing or system readiness. However, evidence from chronic illness populations suggests that immune targeted interventions can produce variable or adverse outcomes when applied during periods of instability (Komaroff and Lipkin, 2021; Scheibenbogen et al., 2020).
TRI produces a different prioritization pathway. Metabolic regulation targets such as PPARGC1A are elevated due to their alignment with energy dysfunction, while environmental response pathways such as AHR are considered based on sensitivity patterns observed in both ME/CFS and autoimmune disease. At the same time, immune checkpoint targets such as PDCD1 are deferred due to high timing sensitivity and the risk of destabilization during active immune fluctuation. This sequencing reflects broader findings across autoimmune and inflammatory disease. In systemic lupus erythematosus, disease activity fluctuates significantly, and treatment response is highly dependent on timing relative to flare state (Tsokos, 2011; Kaul et al., 2016). In rheumatoid arthritis and related autoimmune conditions, early intervention improves outcomes, but inappropriate timing or patient selection can lead to suboptimal response or increased adverse effects (Smolen et al., 2016).
Intervention within TRI is therefore conditional. Pre-intervention thresholds include reduction in environmental load, stabilization of metabolic baseline, and decreased flare frequency. These conditions align with observations from both post-viral and autoimmune disease management, where stabilization phases improve treatment tolerability and effectiveness (Institute of Medicine, 2015; Komaroff and Lipkin, 2021). This approach integrates directly with CYNAERA’s SymCas™ model, which identifies flare trajectories, and the Remission Pathway™, which defines stabilization phases prior to intervention. TRI functions as the decision layer that determines when a biologically relevant target becomes clinically actionable.
By embedding gene-editing strategy within real-world patient dynamics, TRI transforms intervention planning from a theoretical exercise into a controlled, state-aware process that reflects the complexity of immune volatile disease.
System Level Implications and Strategic Positioning
The introduction of TRI extends beyond individual target selection, influencing clinical trial design, regulatory frameworks, and the broader deployment of gene-editing technologies in complex disease environments.
From Target Selection to Readiness Gating
Traditional gene-editing frameworks treat targets as static opportunities for intervention. TRI reframes them as conditional opportunities, dependent on system readiness and timing. This shift aligns with emerging perspectives in precision medicine, where patient state and context are recognized as critical determinants of treatment success (Ashley, 2016; Collins and Varmus, 2015).
Clinical Trial Optimization
Heterogeneity in chronic illness populations remains a major barrier to successful clinical trials. Variability in immune state, environmental exposure, and disease progression contributes to inconsistent outcomes and reduced reproducibility. TRI introduces a method for stratifying participants based on readiness rather than diagnosis alone, improving cohort selection and reducing signal noise. This approach is consistent with recent calls for more precise patient stratification in both autoimmune and post-viral disease research (Boyman et al., 2020; Scheibenbogen et al., 2020).
CRISPR and Autoimmune Translation
Recent advances in CRISPR-based therapies for autoimmune disease, including CAR-T mediated B-cell depletion and gene-modified immune interventions, demonstrate both the promise and complexity of applying gene editing in unstable systems (Mullard, 2023; Georgiadis et al., 2022). These approaches highlight a critical dependency on timing, system context, and pathway interaction, reinforcing the need for frameworks such as TRI.
This dependency is not limited to autoimmune disease. Similar constraints are observed across ME/CFS, Long COVID, and chronic Lyme disease, where immune variability and environmental sensitivity shape intervention risk. TRI provides a unified framework for addressing these challenges across disease categories.
Infrastructure and Licensing Positioning
From a strategic perspective, TRI functions as an infrastructure layer within the broader CYNAERA ecosystem. It integrates with CRISPR Remission™, SymCas™, and environmental modeling frameworks such as Microdosing Air™, enabling a comprehensive approach to intervention design.
This positioning supports multiple applications, including:
Integration into clinical trial design for readiness-based cohort selection
Use in biotech and pharmaceutical pipelines for target validation
Deployment within simulation environments for pathway testing
Application in regulatory and policy frameworks as a safety and readiness standard
By functioning as a gating mechanism rather than a standalone model, TRI establishes a defensible position within the emerging landscape of gene-editing strategy and systems-based medicine.
Conclusion
The expansion of gene-editing technologies into complex chronic illness will not be determined by target discovery alone. It will depend on whether intervention strategies can account for instability, timing sensitivity, and cross system interaction within real-world patient populations. The Target Readiness Index™ provides a structured framework for addressing this challenge. By integrating timing, system interaction, and biological variability into gene target prioritization, TRI shifts the focus from static optimization to dynamic readiness. This approach aligns with emerging evidence across CRISPR research, autoimmune disease, and infection-associated chronic conditions, all of which demonstrate that intervention success depends on more than molecular targeting (Hsu et al., 2014; Frangoul et al., 2021; Mullard, 2023). Instead, it requires alignment between biological state, environmental context, and intervention timing.
TRI establishes this alignment as a core principle of gene-editing strategy. It defines a new approach to CRISPR target prioritization across ME/CFS, Long COVID, Lyme disease, and autoimmune conditions including lupus, type 1 diabetes, Hashimoto’s thyroiditis, and Sjögren’s syndrome. By framing gene editing as a state-dependent process, TRI creates a scalable foundation for safer and more effective intervention across immune-volatile disease. This framework also supports future expansion into additional autoimmune and chronic inflammatory conditions, where timing sensitivity and system instability remain critical barriers to therapeutic success.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17(9), 507–522.
Boyman, O., Comte, D., Spertini, F. (2020). Adverse events associated with biological agents in autoimmune diseases. Nature Reviews Rheumatology, 16(4), 193–208.
Collins, F. S., Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.
Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236.
Frangoul, H., Altshuler, D., Cappellini, M. D., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260.
Georgiadis, C., Preece, R., Nickolay, L., et al. (2022). Long-term follow-up of CRISPR-edited immune cell therapies. Nature Medicine, 28(6), 1235–1243.
Hsu, P. D., Lander, E. S., Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157(6), 1262–1278.
Institute of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. National Academies Press.
Kaul, A., Gordon, C., Crow, M. K., et al. (2016). Systemic lupus erythematosus. Nature Reviews Disease Primers, 2, 16039.
Komaroff, A. L., Lipkin, W. I. (2021). Insights from ME/CFS may help unravel post-acute COVID-19 syndrome. Trends in Molecular Medicine, 27(9), 895–906.
Mullard, A. (2023). CRISPR therapies move closer to mainstream medicine. Nature Reviews Drug Discovery, 22(2), 89–92.
Scheibenbogen, C., Freitag, H., Blanco, J., et al. (2020). Immune abnormalities in ME/CFS. Journal of Translational Medicine, 18, 1–15.
Smolen, J. S., Aletaha, D., McInnes, I. B. (2016). Rheumatoid arthritis. The Lancet, 388(10055), 2023–2038.
Tsokos, G. C. (2011). Systemic lupus erythematosus. New England Journal of Medicine, 365(22), 2110–2121.
Comments